Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - irfan asangani

1 Results Sort By:
Therapy Overcoming Resistance of Refractory Prostate Cancer
Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity. TechnologyProstate cancer (PCa) is the most common non-cutaneous malignancy and the second leading cause of cancer-related death in men of the western world. While ef...
Published: 7/15/2019   |   Inventor(s): Irfan Asangani
Keywords(s):  
Category(s): Therapeutics & Vaccines